| 0 (0%) | 08-02 11:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.66 | 1-year : | 10.48 |
| Resists | First : | 8.27 | Second : | 8.97 |
| Pivot price | 7.91  |
|||
| Supports | First : | 7.13 | Second : | 5.93 |
| MAs | MA(5) : | 7.43 |
MA(20) : | 8.11 |
| MA(100) : | 7.73 |
MA(250) : | 9.35 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 10.5 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 14.96 | Low : | 6.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRMD ] has closed above bottom band by 25.6%. Bollinger Bands are 44.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.56 - 7.6 | 7.6 - 7.63 |
| Low: | 7.21 - 7.25 | 7.25 - 7.29 |
| Close: | 7.46 - 7.53 | 7.53 - 7.59 |
Sat, 01 Aug 2026
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
Fri, 31 Jul 2026
Lobbying Update: $220,000 of CORMEDIX INC. lobbying was just disclosed - Quiver Quantitative
Thu, 30 Jul 2026
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
Thu, 30 Jul 2026
CorMedix (CRMD) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Thu, 30 Jul 2026
CorMedix Inc (CRMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wed, 29 Jul 2026
CorMedix Therapeutics to Report Second Quarter 2026 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 78 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 54.7 (%) |
| Shares Short | 15,350 (K) |
| Shares Short P.Month | 14,510 (K) |
| EPS | 2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | 45.2 % |
| Operating Margin | 49.9 % |
| Return on Assets (ttm) | 26.3 % |
| Return on Equity (ttm) | 65.5 % |
| Qtrly Rev. Growth | 226.1 % |
| Gross Profit (p.s.) | 4.68 |
| Sales Per Share | 5.09 |
| EBITDA (p.s.) | 2.91 |
| Qtrly Earnings Growth | 42.7 % |
| Operating Cash Flow | 198 (M) |
| Levered Free Cash Flow | 120 (M) |
| PE Ratio | 3.47 |
| PEG Ratio | 0 |
| Price to Book value | 1.35 |
| Price to Sales | 1.47 |
| Price to Cash Flow | 2.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|